TrialNature medicine2024

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.

Benjamin Besse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.